Safety Reading Notes

Read safety context beside the research guide.

The GPR55 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 28826536

PubMed For Dummies Article

GPR55 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • GPR55 cannabinoid target currently has 18 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 28826536
  • The evidence classes most visible in the row language are insufficient (14), and mechanistic or pharmacological (4). PMID 34259916
  • The study-design language most visible in the row language is Narrative or expert review (14), Cellular or in vitro study (2), and Animal study (1). PMID 19233486
  • The repeated topics are GPR55 (18), which tells the reader where to start opening PubMed and DOI links. PMID 35862111

Start with the research question

GPR55 cannabinoid target is built from 18 source-backed evidence row(s) and 18 research source(s). The current evidence classes read as insufficient (14), and mechanistic or pharmacological (4), and the study-design language most often reads as Narrative or expert review (14), Cellular or in vitro study (2), and Animal study (1). PMID 28826536

The row-level question is not simply whether GPR55 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are GPR55 (18). PMID 18757503

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 19647110

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 18757503

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 26669245

Limits and uncertainty 14 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 27835801

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 20370712

Where this page has the most source density

The largest bucket surfaced for this page is GPR55: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is GPR55: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 28826536

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 18757503

Bucket chapters: what the literature is circling

GPR55: insufficient

14 research sources 14 rows (926-942) Evidence class: insufficient

This bucket summarizes source-backed rows focused on GPR55: insufficient. It currently draws from 14 research source(s), so the exact study type matters. PMID 28826536

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 28826536

  • Evidence row 926

    Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling,... PMID 28826536

  • Evidence row 942

    CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharma... PMID 41560741

GPR55: mechanistic or pharmacological

4 research sources 4 rows (931, 936, 940, 943) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on GPR55: mechanistic or pharmacological. It currently draws from 4 research source(s), so the exact study type matters. PMID 18757503

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 18757503

  • Evidence row 931

    Endocannabinoids modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity... PMID 18757503

  • Evidence row 936

    CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or ph... PMID 17704827

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 28826536

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 18757503

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 35083862
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 17704827
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 31527410

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 28826536

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 18757503

Source-reading checklist for GPR55 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 17876300
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 20298715
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 17876302
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 26408165
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 41560741

Source Notes

GPR55 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 926

    Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 28826536

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
  2. Evidence row 927

    THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  3. Evidence row 928

    Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 19233486

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The enigmatic pharmacology of GPR55.
  4. Evidence row 929

    Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35862111

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.
  5. Evidence row 930

    Endocannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 19647110

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Is GPR55 an anandamide receptor?
  6. Evidence row 931

    Endocannabinoids modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 18757503

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.
  7. Evidence row 932

    Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 26669245

    Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
  8. Evidence row 933

    Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 27835801

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
  9. Evidence row 934

    Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20370712

    Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
  10. Evidence row 935

    CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35083862

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
  11. Evidence row 936

    CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17704827

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
  12. Evidence row 937

    Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 31527410

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System of Animals.
  13. Evidence row 938

    THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876300

    Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
  14. Evidence row 939

    THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20298715

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological characterization of GPR55, a putative cannabinoid receptor.
  15. Evidence row 940

    CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876302

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The orphan receptor GPR55 is a novel cannabinoid receptor.
  16. Evidence row 941

    Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 26408165

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and Endocannabinoid Signaling in Epilepsy.
  17. Evidence row 942

    CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 41560741

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Epilepsy, neuroinflammation and cannabidiol What do we know thus far?
  18. Evidence row 943

    CBD modulates GPR55; evidence class: mechanistic or pharmacological (outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 36016551

    Evidence class: mechanistic or pharmacological. Source: Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.